# Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

> **NCT01063517** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 124 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** olaparib
- **DRUG:** paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01063517
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-02
- **Primary completion:** 2012-05-11
- **Final completion:** 2023-06-29
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063517, "Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01063517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*